trending Market Intelligence /marketintelligence/en/news-insights/trending/uGmpCDptUk6ZxhPiWFndVQ2 content esgSubNav
In This List

EU expands coverage of Pfizer's antibacterial vaccine

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


EU expands coverage of Pfizer's antibacterial vaccine

The European Commission expanded the coverage of Pfizer Inc.'s Nimenrix to include the use of the antibacterial vaccine in infants as young as six weeks.

Nimenrix is now the only vaccine of its kind that can be administered in European patients from six weeks of age without an upper age limit.